Rani Therapeutics Holdings, Inc. Stock Price, News & Analysis

Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.

The abstract reports that oral semaglutide in dogs was bioequivalent to subcutaneous injections and produced similar weight loss. The poster (No. 647) will be presented by Kyle Horlen, DVM, VP of Nonclinical Development, on November 6, 2025, 2:30–3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1; the meeting is Nov 4–7, 2025 and includes virtual participation.

Rani Therapeutics (Nasdaq: RANI) announced on October 23, 2025 the appointments of Abraham “Abe” Bassan and Vasudev Bailey, Ph.D., to its Board of Directors and the departures of Andrew Farquharson and Maulik Nanavaty.

The company highlighted strategic value from its clinical-stage pipeline and a recent collaboration with Chugai. Rani also closed a previously announced private placement expected to raise approximately $60.3 million, led by Samsara BioCapital with participation from Anomaly, RA Capital, Invus, Special Situations Funds and executive chairman Mir Imran.

Rani Therapeutics (Nasdaq: RANI) closed an oversubscribed private placement on October 23, 2025, raising $60.3 million in gross proceeds via at-the-market pricing under Nasdaq rules.

The financing included issuance of 42,633,337 shares at $0.48 and pre-funded warrants for up to 82,366,667 shares at $0.4799, plus accompanying warrants exercisable upon stockholder approval to purchase up to 125,000,004 shares at $0.48 (5-year term). Samsara led the round; Samsara and Anomaly each gain the right to designate a board member. The company says net proceeds, a $10.0M upfront payment and an expected $18.0M milestone are expected to fund operations into 2028 and support the RaniPill platform.

Rani Therapeutics (Nasdaq: RANI) priced an oversubscribed private placement expected to raise approximately $60.3 million in gross proceeds, with closing targeted on or about October 21, 2025. The financing includes 42,633,337 shares at $0.48 each and pre-funded warrants for up to 82,366,667 shares at $0.4799 each, plus accompanying warrants to purchase up to 125,000,004 shares exercisable upon stockholder approval.

The company said net proceeds, together with a $10.0 million upfront payment and an expected $18.0 million technology-transfer milestone from a Chugai collaboration, are expected to fund operations into 2028. Samsara and Anomaly will each gain the right to designate a board member; Avenue converted $6.0 million of debt into equity as part of the transaction.

Rani Therapeutics (Nasdaq: RANI) announced a Collaboration and License Agreement with Chugai on October 17, 2025 to develop an oral product using RaniPill and a Chugai rare‑disease antibody.

Key terms: $10 million upfront, up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones, single‑digit royalties, and an option for Chugai to add up to five additional targets — bringing total potential deal value to $1.085 billion. Rani also announced an oversubscribed $60.3 million PIPE led by Samsara BioCapital; net proceeds plus upfront and an expected $18.0 million technology transfer milestone are expected to fund operations into 2028.

Rani Therapeutics (NASDAQ:RANI) reported Q2 2025 financial results and corporate updates. The company announced a strategic research collaboration with Chugai for two undisclosed molecules and presented promising preclinical data for RT-114, their novel oral bispecific GLP-1/GLP-2 receptor agonist for obesity treatment.

Financial highlights include a $4.3 million warrant inducement transaction and a $3.0 million registered direct offering. Cash position stood at $10.2 million as of June 30, 2025, down from $27.6 million at year-end 2024. The company reported a reduced net loss of $11.2 million compared to $13.4 million in Q2 2024, with decreased R&D and G&A expenses.

Rani plans to initiate a Phase 1 clinical trial for RT-114 in obesity treatment during H2 2025.

Rani Therapeutics (NASDAQ: RANI), a clinical-stage biotherapeutics company, has announced a $3.0 million registered direct offering of its Class A common stock and pre-funded warrants. The company will sell 4,354,000 shares at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999 to a single institutional investor.

The offering, expected to close around July 16, 2025, is being conducted through Maxim Group LLC as the sole placement agent. The pre-funded warrants will have an exercise price of $0.0001 per share. The offering is made pursuant to an effective shelf registration statement, with proceeds subject to placement agent fees and offering expenses.

Rani Therapeutics (NASDAQ: RANI) announced it will present preclinical data for its RaniPill® capsule at ENDO 2025 in San Francisco. The presentation will showcase research demonstrating bioequivalence between oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) using their robotic pill (RT-114) and traditional subcutaneous injection in canines.

The poster presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114)," will be presented by Dr. Anvesh Dasari on July 14, 2025, from 12:00 PM to 1:30 PM PT, as part of the session on adipose tissue, appetite, and obesity therapeutic advances.

Rani Therapeutics (NASDAQ: RANI) has announced a Research Agreement with Chugai Pharmaceutical to evaluate the feasibility of applying Rani's oral delivery technology to Chugai's antibodies. The agreement, signed on August 13, 2024, covers two molecules with undisclosed targets. Initial analysis shows the RaniPill® delivery system achieved comparable bioavailability to subcutaneous delivery for both studied molecules.

Rani has previously evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill® capsule. The collaboration aims to leverage Rani's expertise in developing oral antibodies, peptides, and large proteins with high bioavailability alongside Chugai's technology-driven drug discovery approach.